Edgemond James, who serves as Chief Financial Officer and Treasurer of United Therapeutics (NASDAQ: UTHR), executed a block of share sales totaling $5.36 million on March 26, 2026. The disposition involved 9,990 shares of common stock sold at prices ranging from $532.0242 to $540.0438 per share.
On the same day Mr. James exercised stock options for 10,000 shares of United Therapeutics, doing so at an exercise price of $135.42. The exercise represented a total value of $1,354,199.
Both the stock sales and the option exercise were carried out pursuant to a Rule 10b5-1 trading plan that James established on October 31, 2025. After these transactions, he directly holds 18,876 shares of United Therapeutics common stock.
The sales occurred while United Therapeutics shares were trading near their 52-week high of $549.50, after a one-year gain of 73%, according to InvestingPro data. InvestingPro’s Fair Value analysis indicates the stock is slightly overvalued at the levels where the trades were executed.
Company developments and clinical news
In parallel with the insider transactions, United Therapeutics disclosed a $2.0 billion stock repurchase program. The company initiated the program with accelerated share repurchase agreements totaling $1.5 billion with Citibank, and it retains the option to repurchase an additional $500 million in shares at its discretion over the next year.
United Therapeutics also released results from its phase 3 TETON-2 clinical study, which evaluated nebulized Tyvaso in patients with idiopathic pulmonary fibrosis. The TETON-2 trial met its primary endpoint, showing a statistically significant improvement in lung function relative to placebo.
Following the clinical and capital-market developments, Cantor Fitzgerald revised its price target for United Therapeutics to $625 and maintained an Overweight rating, citing favorable expectations tied to the company’s TETON-1 trial. TD Cowen reiterated a Buy rating and set a $575 price target, expressing confidence in the company’s strategic direction.
Context for investors
The insider sale and option exercise were conducted via a pre-established 10b5-1 plan, and the company-level announcements highlight both capital return activity and clinical progress. The combination of insider transactions, a substantial repurchase program, and positive phase 3 data contributes to an active near-term profile for United Therapeutics stock.
Investors seeking more detailed breakdowns of executive transactions and additional InvestingPro analysis may consult the platform for expanded coverage and proprietary valuation commentary.